Sibrotuzumab Biosimilar – Anti-FAP mAb – Research Grade

The Structure of Sibrotuzumab Biosimilar – Anti-FAP mAb

Sibrotuzumab Biosimilar, also known as Anti-FAP mAb, is a monoclonal antibody (mAb) that targets the fibroblast activation protein (FAP). It is a biosimilar of the original Sibrotuzumab, which was developed by the biopharmaceutical company Boehringer Ingelheim for the treatment of cancer. Sibrotuzumab Biosimilar is a research grade antibody that is used in laboratory studies to understand the structure, function, and potential therapeutic applications of FAP.

FAP is a cell surface protein that is highly expressed on cancer-associated fibroblasts, which are cells that support the growth and progression of tumors. FAP is also found on the surface of activated fibroblasts in various other diseases, such as fibrosis and inflammation. This makes it an attractive therapeutic target for a wide range of diseases.

Sibrotuzumab Biosimilar is a humanized IgG1 antibody, meaning that it is derived from human antibodies and has a similar structure to the antibodies produced by our immune system. It consists of two heavy chains and two light chains, which are connected by disulfide bonds. The variable regions of the antibody, which are responsible for binding to FAP, are located at the tips of the two heavy and two light chains. This unique structure allows Sibrotuzumab Biosimilar to specifically bind to FAP and block its activity.

The Activity of Sibrotuzumab Biosimilar – Anti-FAP mAb

Sibrotuzumab Biosimilar works by binding to FAP on the surface of cells and blocking its activity. FAP has been shown to have a role in promoting tumor growth and metastasis, as well as contributing to fibrosis and inflammation. By targeting FAP, Sibrotuzumab Biosimilar can potentially inhibit these processes and have therapeutic effects.

In laboratory studies, Sibrotuzumab Biosimilar has been shown to effectively bind to FAP and block its enzymatic activity. This activity has been demonstrated in various cancer cell lines, as well as in animal models of cancer and other diseases. Sibrotuzumab Biosimilar has also been shown to have anti-tumor effects, including inhibiting tumor growth and reducing metastasis, in preclinical studies.

The Application of Sibrotuzumab Biosimilar – Anti-FAP mAb

Sibrotuzumab Biosimilar has potential applications in the treatment of various diseases, particularly cancer. As a biosimilar of Sibrotuzumab, it has the potential to be used as a therapeutic antibody for the treatment of FAP-expressing cancers, such as pancreatic, colorectal, and breast cancer. It may also have applications in other diseases where FAP is involved, such as fibrosis and inflammation.

In addition to its potential therapeutic applications, Sibrotuzumab Biosimilar is also used in laboratory research to study the role of FAP in disease progression and to develop new treatments targeting FAP. Its high specificity and activity against FAP make it a valuable tool for understanding the function of this protein and its potential as a therapeutic target.

In conclusion, Sibrotuzumab Biosimilar – Anti-FAP mAb is a research grade antibody that specifically targets FAP, a cell surface protein involved in various diseases. Its unique structure and activity make it a promising candidate for the treatment of FAP-expressing cancers and other diseases. Its use in laboratory research also provides valuable insights into the role of FAP in disease progression and potential therapeutic strategies.